The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
Almost in stealth mode the Swiss firm moves to begin a huge pivotal programme rivalling that of the IDO and IL-2 mechanisms.
As a US adcom gives the strongest possible indication that oxycodegol won’t be approved, Nektar’s valuation loses 11%.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
The French drugmaker bets big as it plays catch-up in the immuno-oncology space with a next-generation IL-2 buyout.
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.